These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32631634)

  • 1. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
    Ohgami M; Kaburagi T; Kurosawa A; Doki K; Shiozawa T; Hizawa N; Homma M
    Ther Drug Monit; 2018 Dec; 40(6):699-704. PubMed ID: 29995672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
    Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
    Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Emoto-Yamamoto Y; Iida S; Kawanishi T; Fukuoka M
    J Clin Pharm Ther; 2015 Apr; 40(2):232-9. PubMed ID: 25402940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.
    Liao D; Yao D; Liu N; Cao L; Xiang D; Yang N; Zhang Y; Jiang W; Zhou C
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):551-559. PubMed ID: 30039303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
    Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
    Waller LL; Miller AA; Petty WJ
    Lung Cancer; 2010 Jan; 67(1):12-6. PubMed ID: 19762110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Garrett M; Taylor T; Mould DR; Amantea MA; Chen Y; Ingrosso A; Pithavala YK
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
    Wu Q; Li MY; Li HQ; Deng CH; Li L; Zhou TY; Lu W
    Acta Pharmacol Sin; 2013 Nov; 34(11):1427-36. PubMed ID: 24096601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations.
    Takeda Y; Ishizuka N; Sano K; Hirano S; Suzuki M; Naka G; Sugiyama H
    Clin Transl Sci; 2020 Nov; 13(6):1150-1160. PubMed ID: 32315488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
    Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
    Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
    Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
    Catalán-Latorre A; Sureda M; Brugarolas-Masllorens A; Escudero-Ortiz V
    Ther Drug Monit; 2021 Aug; 43(4):447-450. PubMed ID: 33840795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib in non-small-cell lung cancer.
    Gridelli C; Rossi A; Maione P; Colantuoni G; Del Gaizo F; Ferrara C; Nicolella D; Guerriero C
    Expert Opin Pharmacother; 2007 Oct; 8(15):2579-92. PubMed ID: 17931092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.